The meeting had more than 2,500 registrants attending in person or online. JZP458, which is approved in the United States and Canada, is a new Erwinia-derived asparaginase. The retrospective, observational study included adults who received their first allogeneic HSCT during their first remission. Dr. Coombs discusses her journey into oncology, what it’s like to broach the lymphoid and myeloid worlds, and a unique ... Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM. Othman Al-Sawaf, MD, and Nicole Lamanna, MD, debate approaches in this Point | Counterpoint. Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches." Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question. It is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase. The application for the approval of epcoritamab is based on results from the phase I/II EPCORE NHL-1 trial. The supplemental BLA submission is supported by data from the CARTITUDE-4 study. The FDA has put a clinical hold on the investigational new drug CART-ddBCMA. Dr. Mascarenhas and colleagues identified 11,371 patients with myelofibrosis, finding that 76.8% had concurrent anemia. Dose reduction may be a strategy to mitigate the risk of cardiac AEs from recurring or worsening in B-cell malignancies. Luspatercept-aamt demonstrated “favorable outcomes” compared with epoetin alfa across common mutations in MDS. The estimated seven-year EFS rate was 76.7% in patients receiving rituximab maintenance. Revumenib is a potent, selective oral inhibitor of interaction between menin and KMT2A. Exposure to thalidomide analogs is associated with TP53 mutations in patients with therapy-related myeloid neoplasms. Given the multitude of novel therapies recently approved, clinicians must consider how to best sequence the options. CAR-T therapy leads to responses in most patients with aggressive B-cell lymphoma, but durable CRs only occur in a minority.